Is Mounjaro a Semaglutide? No, and Here's What It Actually Is

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 9 sources cited

Key Takeaways

• Mounjaro is not semaglutide. Mounjaro contains tirzepatide, a different molecule made by a different manufacturer.
• Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus, all made by Novo Nordisk.
• Tirzepatide is a dual GLP-1 and GIP receptor agonist. Semaglutide is a GLP-1 receptor agonist only.
• In head-to-head trials, tirzepatide produced more weight loss and stronger A1C reduction than semaglutide.
• The drugs are similar in dosing schedule (once weekly) and side effect categories but are not interchangeable.

Direct answer (40-60 words)

No, Mounjaro is not a semaglutide. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist made by Eli Lilly. Semaglutide is a single GLP-1 receptor agonist made by Novo Nordisk and sold as Ozempic, Wegovy, and Rybelsus. The two drugs share a class but are different molecules.

Table of contents

1. The 30-second answer
2. What Mounjaro actually is
3. What semaglutide actually is
4. Why people confuse the two
5. The molecular and mechanistic differences
6. Head-to-head trial results
7. Side effect comparison
8. Cost and insurance differences
9. Switching between tirzepatide and semaglutide
10. FAQ
11. Sources

What Mounjaro actually is

Mounjaro is the brand name for tirzepatide, an injectable peptide medication made by Eli Lilly. The FDA approved Mounjaro in 2022 for type 2 diabetes (FDA, 2022).

Tirzepatide is a dual incretin receptor agonist. It activates two receptors:

• GLP-1 (glucagon-like peptide-1)
• GIP (glucose-dependent insulinotropic polypeptide)

Both receptors are part of the body's incretin system. GLP-1 and GIP are gut hormones the body releases after meals to regulate insulin, blood sugar, gastric emptying, and appetite. Tirzepatide imitates both hormones at therapeutic doses.

Mounjaro is delivered as a once-weekly subcutaneous injection in a single-dose auto-injector pen. Doses run from 2.5 mg through 15 mg, escalated over weeks based on tolerance and clinical response.

Mounjaro's twin drug, Zepbound, contains the same active ingredient (tirzepatide) and is FDA-approved for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Zepbound was approved in 2023.

What semaglutide actually is

Semaglutide is the active ingredient in three Novo Nordisk drugs:

• Ozempic (FDA-approved for type 2 diabetes, 2017)
• Wegovy (FDA-approved for chronic weight management, 2021)
• Rybelsus (oral semaglutide, FDA-approved for type 2 diabetes, 2019)

Semaglutide is a GLP-1 receptor agonist. It activates the GLP-1 receptor only, not the GIP receptor. This is the single most important mechanistic difference from tirzepatide.

GLP-1 activation produces appetite suppression, slowed gastric emptying, increased insulin secretion in response to meals, and reduced glucagon output from the liver. These effects produce both blood-glucose control in diabetes and weight loss in obesity.

Ozempic and Wegovy are once-weekly subcutaneous injections delivered in multi-dose pens. Doses run from 0.25 mg through 2 mg for Ozempic and from 0.25 mg through 2.4 mg for Wegovy.

Rybelsus is a daily oral tablet at 3 mg, 7 mg, or 14 mg.

Why people confuse the two

The two drugs get confused for several practical reasons:

1. Same drug class. Both are GLP-1-related medications. Marketing copy and casual conversation often use "GLP-1" as a category that covers both, even though tirzepatide is technically a GLP-1 + GIP combination, not a pure GLP-1.
2. Same delivery method. Both are once-weekly subcutaneous injections at maintenance.
3. Similar side effect profile. Nausea, constipation, reflux, and other GI symptoms show up on both.
4. Similar use cases. Both are used for type 2 diabetes and weight loss.
5. Branding overlap. "Ozempic" became shorthand for the entire category in popular culture, the way "Kleenex" became shorthand for tissues. People say "Ozempic" when they mean any GLP-1.

The active ingredients are different molecules with different receptor targets. They're not interchangeable, and the FDA approves them separately for different specific uses at different doses.

The molecular and mechanistic differences

Both drugs slow gastric emptying, suppress appetite, and improve insulin response. The dual mechanism of tirzepatide adds GIP receptor activity, which appears to amplify both insulin secretion and weight-loss effect compared to GLP-1 activation alone (Frias et al., NEJM 2021).

The dose numbers are not comparable. A patient on Mounjaro 5 mg and a patient on Ozempic 1 mg are at completely different dose levels of completely different drugs. There is no direct mg-for-mg conversion.

Head-to-head trial results

Eli Lilly funded a direct head-to-head trial of tirzepatide versus semaglutide in patients with type 2 diabetes (SURPASS-2, Frias et al., NEJM 2021).

A1C reduction at 40 weeks:

Weight loss at 40 weeks (T2D patients):

Tirzepatide produced more weight loss and stronger A1C reduction at every dose level tested. The advantage was larger at higher doses.

For non-diabetic obesity, the cleanest comparison is between two separate trials:

• STEP 1 (semaglutide 2.4 mg, Wilding et al., NEJM 2021): 14.9% body weight loss at 68 weeks
• SURMOUNT-1 (tirzepatide 15 mg, Jastreboff et al., NEJM 2022): 20.9% body weight loss at 72 weeks

A roughly 6 percentage point gap in average weight loss favors tirzepatide. Real-world cohort data (Rodriguez et al., JAMA Internal Medicine 2024) replicates the gap in non-trial settings.

The data is consistent: at maximum dose, tirzepatide outperforms semaglutide for both weight loss and A1C reduction. Individual response varies. Some patients tolerate or respond better to semaglutide.

Side effect comparison

Both drugs share the same general side effect categories. Severity differs slightly.

Both drugs carry the same boxed warning for thyroid C-cell tumors, based on rodent studies. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Patient experience varies more than the percentages suggest. Some patients tolerate tirzepatide much better than semaglutide; some have the opposite experience. The "right" drug for an individual patient often comes down to side effect tolerance more than mechanism.

Cost and insurance differences

Cash prices are roughly comparable.

Manufacturer savings cards exist for both drug families:

• Novo Nordisk savings cards for Ozempic and Wegovy reduce eligible commercial-insurance copays to $25 or lower.
• Eli Lilly savings cards for Mounjaro and Zepbound do the same.

Insurance coverage for the two drug families isn't always parallel. Some plans cover Ozempic but not Mounjaro, or vice versa. Some prefer one drug at a lower tier and the other at a higher tier. The choice between drugs sometimes comes down to which one your specific plan covers cheaper.

For more on the cost side, see /articles/cost-and-insurance/mounjaro-cost/ and /articles/cost-and-insurance/cheap-glp1/.

Switching between tirzepatide and semaglutide

Patients can switch from one to the other under provider supervision. Switching is common when:

• Side effects on the first drug are intolerable
• The first drug doesn't produce expected weight loss or A1C reduction at maximum tolerated dose
• Insurance coverage changes
• Cost on the first drug becomes unsustainable

When switching:

• The new drug usually starts at its lowest dose, not at an "equivalent" higher dose. There is no clean conversion table.
• The titration schedule for the new drug applies. A patient on Ozempic 2 mg switching to Mounjaro typically starts at Mounjaro 2.5 mg and works up.
• Some side effects from the original drug take 4-6 weeks to fully resolve. New side effects from the second drug may layer on during the transition.
• Weight may stabilize or slightly increase during the switch as the second drug titrates up.

Most providers recommend a 12-16 week trial at maximum tolerated dose of the original drug before switching, because both drugs need time to show their full effect.

For a deeper comparison of the two drug families, see /articles/comparison/difference-between-ozempic-mounjaro/.

FAQ

Is Mounjaro a semaglutide? No. Mounjaro is tirzepatide, a dual GLP-1 and GIP receptor agonist made by Eli Lilly. Semaglutide is a different molecule made by Novo Nordisk and sold as Ozempic, Wegovy, and Rybelsus.

Is tirzepatide the same as semaglutide? No. Tirzepatide and semaglutide are different molecules with different receptor targets. Tirzepatide hits both GLP-1 and GIP receptors. Semaglutide hits only GLP-1.

What is Mounjaro's active ingredient? Tirzepatide. Mounjaro is the Eli Lilly brand name for the tirzepatide molecule. Zepbound, also Eli Lilly, contains the same tirzepatide molecule and is FDA-approved for weight loss.

What is Ozempic's active ingredient? Semaglutide. Ozempic is the Novo Nordisk brand name for injectable semaglutide approved for type 2 diabetes. Wegovy contains the same semaglutide and is approved for weight loss.

Are Mounjaro and Ozempic in the same drug class? They share a drug class (incretin receptor agonists) but have different mechanisms. Ozempic is a single-receptor GLP-1 agonist. Mounjaro is a dual GLP-1 and GIP agonist.

Which is stronger, Mounjaro or Ozempic? On average, tirzepatide produces more weight loss and stronger A1C reduction than semaglutide at maximum dose. SURPASS-2 showed tirzepatide 15 mg outperformed semaglutide 1 mg on both endpoints.

Can I take Mounjaro and Ozempic together? No. They work on overlapping receptors. Combining them increases side effect risk without proportional benefit. Patients who don't tolerate one usually switch to the other rather than stacking.

Is Mounjaro approved for weight loss? Mounjaro is FDA-approved for type 2 diabetes only. The same active ingredient (tirzepatide) at similar doses is approved for weight loss under the brand name Zepbound. Mounjaro for weight loss is off-label.

Is Ozempic approved for weight loss? Ozempic is FDA-approved for type 2 diabetes only. Wegovy contains the same active ingredient (semaglutide) at a higher dose and is approved for weight loss. Ozempic for weight loss is off-label.

Can I switch from Ozempic to Mounjaro? Yes, with provider guidance. The new drug starts at its own lowest dose, not at an equivalent dose. Switching typically takes 12-16 weeks to fully retitrate. Common reasons include side-effect intolerance or weight-loss plateau.

Is compounded semaglutide the same as Mounjaro? No. Compounded semaglutide contains semaglutide, the same active ingredient as Ozempic and Wegovy. Mounjaro contains tirzepatide. They are different molecules. Some pharmacies also offer compounded tirzepatide, which contains the same active ingredient as Mounjaro.

Why does this confusion happen? Both drugs are once-weekly injectables in the same class with similar marketing. People often use "Ozempic" as a generic term for any GLP-1 medication. Knowing the active ingredient (semaglutide vs tirzepatide) and the manufacturer (Novo Nordisk vs Eli Lilly) usually clears it up.

Sources

1. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503-515.
2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
3. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
4. Rodriguez J, et al. Comparative effectiveness of tirzepatide and semaglutide for weight reduction. JAMA Intern Med. 2024;184(8):907-915.
5. Mounjaro prescribing information. Eli Lilly. Revised 2024.
6. Ozempic prescribing information. Novo Nordisk. Revised 2024.
7. Wegovy prescribing information. Novo Nordisk. Revised 2024.
8. Zepbound prescribing information. Eli Lilly. Revised 2024.
9. FDA. Mounjaro Approval Letter. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.